Funding Opportunity Title
U.S. - India Bilateral Brain Research Collaborative Partnerships (U.S. - India BRCP) (R21)
R21 Exploratory/Developmental Research Grant Award
Funding Opportunity Announcement (FOA) Number
Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.853; 93.279; 93.242
This FOA is issued by three NIH Institutes (NINDS, NIMH and NIDA) under the Department of Health and Human Services (HHS) of the United States of America (U.S.) and the Department of Biotechnology (DBT) under the Ministry of Science and Technology (MoST) of the Republic of India (India).
The purpose of this program is to support the establishment and enhancement of bilateral research collaborations between U.S. and Indian investigators in the field of neuroscience with an emphasis on understanding, treating and curing neurological, mental and addictive disorders. Specific areas of research may include, but are not limited to, studies of mechanisms underlying neurological, mental and addictive disorders and diseases, planning for population-based research and clinical trials, the development of infrastructures for resource, tool and data sharing in addition to projects aimed at advancing global health research, particularly as it relates to the mission of the participating organizations.
The collaboration/partnership must involve at least one U.S. investigator (PD/PI) from an eligible U.S. institution and one or more Indian investigator (PD/PI) who is affiliated with an eligible Indian institution, as determined by the DBT. Applications supported by this program must involve integrated research projects that are enhanced by the inclusion of both U.S. and Indian components. Research applications should be submitted as a single application by the U.S. Institution to the NIH.
January 14, 2011
Open Date (Earliest Submission Date)
February 22, 2011
Letter of Intent Due Date
February 22, 2011
Application Due Date(s)
March 22, 2011 , by 5:00 PM local time of applicant organization.
AIDS Application Due Date(s)
Scientific Merit Review
Advisory Council Review
Earliest Start Date(s)
March 23, 2011
Due Dates for E.O. 12372
Required Application Instructions
It is critical that applicants follow the instructions in the SF 424 (R&R) Application Guide except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.
Part 1. Overview Information
Part 2. Full Text of the Announcement
Section I. Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission Information
Section V. Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information
The purpose of the U.S.-India Brain Research Collaborative Partnerships (BRCP) Program (R21) is to support the establishment and enhancement of bilateral research collaborations between U.S. and Indian investigators in the field of neuroscience with an emphasis on understanding, treating and curing neurological, mental and addictive disorders. Specific areas of research may include, but are not limited to, studies of mechanisms underlying neurological, mental and addictive disorders and diseases, planning for population-based research and clinical trials, development of infrastructure for resource, tool and data sharing in addition to projects aimed at advancing global health research, particularly as it relates to the mission of the participating organizations.
The collaboration/partnership must involve a U.S. investigator (PD/PI) from an eligible U.S. institution and at least one Indian investigator (PD/PI) who is affiliated with an eligible Indian institution (as determined by the DBT). Applications supported by this program must involve integrated research projects that are enhanced by the inclusion of both U.S. and India components. Successful applications will include a well-presented justification for the bilateral collaboration, and detailed experimental approaches that will be completed by each component. Research applications should be submitted as a single application by the U.S. Institution to the NIH.
This program will use the R21 grant mechanism to support up to two years of exploratory/ developmental collaborative research. All applications should include separate budgets for the U.S. and Indian component, respectively.
In 2005, the U.S. and Indian government signed an Agreement on Science and Technology, which encourages cooperation between the U.S. and India to promote advances in each area.
Recognizing that research collaborations addressing neurological, mental and addictive disorders would be of mutual benefit to both nations, in 2008 the NINDS, NIMH and NIDA under the NIH, HHS of the U.S., established a “Joint Statement on Research Related to Mental Health, Neurology and Addictive Disorders” with DBT under the MoST of India.
This U.S.-India BRCP is designed to implement the Joint Statement by encouraging high quality bilateral research collaborations that could lead to new biomedical discoveries with the potential of reducing the neurological, mental and addictive disease burden borne by people in both nations and throughout the world.
Scope of Research
This R21 program will support innovative, exploratory/developmental collaborative research. The type of research activities encouraged by this program includes, but is not limited to:
Collaborative Research Partnerships
A critical feature of this FOA is the establishment of BRCPs among investigators and institutions in the U.S. and India. Applications may be derived from existing formal or informal collaborations with a history of interaction, or from new partnerships developed in response to this FOA. The BRCP must be based on a closely interactive partnership that maximizes the expertise of the research partners from both countries.
Health research is one of the top priorities of both U.S. and Indian governments. With the improvement of socio-economic conditions and increased global life expectancy, chronic non-communicable diseases, including neurological, mental and addictive disorders, impose more challenges to global health than ever before. The combination of high prevalence, early onset, persistence and impairment makes these disorders a major contributor to the total global disease burden. For example, neurological and neurovascular disorders are among the leading causes of mortality and disability worldwide. Some of these disorders might have distinct genetic backgrounds or special environmental factors (e.g., high prevalence of early-onset stroke in Indian populations). Similarly, unipolar depression is expected to become the leading cause of disability in the next decade. Depressive disorders often co-occur with neurological and substance use disorders. World-wide alcohol, tobacco, and illicit drug abuse are responsible for considerable mortality and morbidity.
Comparative studies of brain disorders in the Asian Indian populations in the U.S. and in India might shed light on the genetic and epigenetic mechanisms underlying the disorders, and provide insight for prevention and treatment at a population-specific level. Collaborative research in computational neuroscience involving neuroscientists, computer scientists, engineers, mathematicians, statisticians, theoreticians and others is needed to advance our understanding of the nervous system and dynamic complex mechanisms underlying neurological and psychiatric brain disorders.
Research projects should address mechanistic, translational and clinical research of neurological, mental and addictive disorders.
Disease priority areas may include, but are not limited to:
Research approaches may include, but are not be limited to:
Research areas may include, but are not be limited to:
Applicants are strongly encouraged to consult with NIH Program Staff as plans for an application are being developed. This early contact will provide an opportunity to clarify the applicant's understanding of program goals and guidelines.
Application Types Allowed
Funds Available and Anticipated Number of Awards
The number of awards is contingent upon NIH appropriations, and the submission of a sufficient number of meritorious applications.
Direct costs for each component (U.S. or Indian) of the application are limited to $275,000 USD over a two-year period, with no more than $200,000 USD in direct costs allowed in any single year for each component. The NIH will only provide funds to support the U.S. component and the DBT will only provide funds to support the Indian component. A complete budget for the Indian component must be included as part of the Budget Justification section of the application.
Award Project Period
The total project period for an application submitted in response to this funding opportunity may not exceed two years..
NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made in response to this FOA.
Higher Education Institutions:
The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:
Nonprofits Other Than Institutions of Higher Education
For profit Organizations
Non-domestic (non-U.S.) Entities (Foreign Organizations) are
not eligible to apply.
Foreign (non-U.S.) components of U.S. Organizations are allowed.
All proposed collaborations must involve at least one U.S. investigator from an eligible U.S. institution and one or more Indian investigator who is affiliated with an eligible Indian institution, as determined by the DBT. Applications that do not include an Indian component with a detailed budget will not be considered.
Applicant organizations must complete the following registrations
as described in the SF 424 (R&R) Application Guide to be eligible to apply
for or receive an award. Applicants must have a valid Dun and Bradstreet
Universal Numbering System (DUNS) number in order to begin each of the following
All Program Directors/Principal Investigators (PD/PIs) must
also work with their institutional officials to register with the eRA Commons
or ensure their existing eRA Commons account is affiliated with the eRA Commons
account of the applicant organization.
All registrations must be completed by the application due date. Applicant organizations are strongly encouraged to start the registration process at least four (4) weeks prior to the application due date.
Any individual(s) with the skills, knowledge, and resources
necessary to carry out the proposed research as the Project Director/Principal
Investigator (PD/PI) is invited to work with his/her organization to develop an
application for support. Individuals from underrepresented racial and ethnic
groups as well as individuals with disabilities are always encouraged to apply
for NIH support.
For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF 424 (R&R) Application Guide.
This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.
Applicant organizations may submit more than one application, provided that each application is scientifically distinct.
NIH will not accept any application in response to this FOA that is essentially the same as one currently pending initial peer review unless the applicant withdraws the pending application. NIH will not accept any application that is essentially the same as one already reviewed.
Applicants must download the SF424 (R&R) application package associated with this funding opportunity using the “Apply for Grant Electronically” button in this FOA or following the directions provided at Grants.gov.
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.
By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:
Descriptive title of proposed research
Name, address, and telephone number of the PD(s)/PI(s)
Names of other key personnel
Number and title of this funding opportunity
The letter of intent should be sent to:
Stacey D. Chambers, M.S.
Office of International Activities
National Institute of Neurological Disorders and Stroke
6001 Executive Boulevard
Neuroscience Center, Room 2179
Bethesda, MD 20892-9523
The forms package associated with this FOA includes all applicable components, mandatory and optional. Please note that some components marked optional in the application package are required for application submission. Follow all instructions in the SF424 (R&R) Application Guide to ensure you complete all appropriate “optional” components.
All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:
Resource Sharing Plan
Individuals are required to comply with the instructions for the Resource Sharing Plans (Data Sharing Plan, Sharing Model Organisms, and Genome Wide Association Studies (GWAS) as provided in the SF424 (R&R Application Guide), with the following modifications:
Do not use the appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
Part I. Overview Information contains information about Key Dates. Applicants are encouraged to submit in advance of the deadline to ensure they have time to make any application corrections that might be necessary for successful submission.
Organizations must submit applications via Grants.gov, the online portal to find and apply for grants across all Federal agencies. Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration.
Under this FOA, only the U.S. institution and U.S. PD/PI are required to register in eRA Commons. Registration is not required for the Indian institution or the Indian Co-Investigator.
Applicants are responsible for viewing their application in the eRA Commons to ensure accurate and successful submission.
Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.
This initiative is not subject to intergovernmental review.
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Pre-award costs are allowable only as described in the NIH Grants Policy Statement.
Applications must be submitted electronically following the instructions described in the SF 424 (R&R) Application Guide. Paper applications will not be accepted.
Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.
For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically.
All PD/PIs must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF 424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH.
The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization’s profile in the eRA Commons and for the Central Contractor Registration (CCR). Additional information may be found in the SF424 (R&R) Application Guide.
See more tips for avoiding common errors.
Upon receipt, applications will be evaluated for completeness by the Center for Scientific Review , NIH. Applications that are incomplete will not be reviewed.Note: All applications for the U.S.–India BRCP must be submitted from the U.S. Institution
Applications must include a Collaboration Plan describing how the proposed collaboration will be maintained throughout the duration of the award. The following areas should be addressed:
The Collaboration Plan may be up to three pages in length and should be included as an attachment to the Research & Related Other Project Information form under item 12"Other Attachments" in the SF424 (R&R). The filename “Collaboration_Plan.pdf” should be used and will be reflected in the final application image bookmarking for easy access by reviewers. The Collaboration Plan is not included in the 6-page limit of the Research Plan.
Each application must include separate budgets for the U.S. and Indian components respectively. Within the application, the U.S. applicant should include a budget detailing all costs associated with his/her component of the project. The budget for the Indian investigator/collaborator should be included in the Budget Justification section of the application and must also include detailed information of all costs associated with that component of the project.
The budget limitations for Indian collaborators/institutions are the same as those of the U.S. investigator (PD/PI). Direct costs are limited to $275,000 USD over an R21 two-year period, with no more than $200,000 USD in direct costs allowed in any single year. If an application is selected for funding, the NIH will only provide funds to support the U.S. component. The Indian component will be supported by the DBT.
The NINDS will not accept unsolicited R21 applications that include clinical trials or other clinical studies of potential therapies. NINDS places a high priority on the development and evaluation of such clinical interventions and has established specific mechanisms for supporting these types of applications (see http://www.ninds.nih.gov/funding/funding_announcements/Funding-Bins-Clinical-Research.htm).
R21 applications that involve human subjects may be submitted to NINDS if the applications do not include any clinical intervention AND if safety monitoring of study participants can be performed appropriately within the budgetary and time constraints of an R21. Any R21 application that does not meet the above criteria or does not provide adequate plans for the protection of the safety, privacy and confidentiality of study participants will not be funded.
The NIH encourages investigators, who conduct genetics and related projects, to utilize the NIH Neuroscience Blueprint Resources such as genetic repositories to share their genetic samples and data. (http://neuroscienceblueprint.nih.gov/neuroscience_resources/cell_tissue.htm#repositories )
These resources include, but are not limited to, the following:
Investigators might also want to consider use of the NIH database of Genotypes and Phenotypes (dbGAP; http://www.ncbi.nlm.nih.gov/gap) or other resources that encourage sharing of genotyping data while simultaneously protecting privacy.
Applicants are required to follow the instructions for post-submission materials, as described in NOT-OD-10-115.
Only the review criteria described below will be considered in the review process. As part of the NIH mission, all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.
The R21 exploratory/developmental grant supports investigation of novel scientific ideas or new model systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. An R21 grant application need not have extensive background material or preliminary information. Accordingly, reviewers will focus their evaluation on the conceptual framework, the level of innovation, and the potential to significantly advance our knowledge or understanding. Appropriate justification for the proposed work can be provided through literature citations, data from other sources, or, when available, from investigator-generated data. Preliminary data are not required for R21 applications; however, they may be included if available.
Reviewers will provide an overall impact/priority score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).
Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.
Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field? Will the project lead to new biomedical discoveries with the potential to reduce the neurological, mental and addictive disease burden borne by people in both nations or across the world?
Are the PD/PIs, collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?
Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed? Does the project make use of unusual expertise, resources, or environment at the Indian site?
Are the overall strategy, methodology, and analyses
well-reasoned and appropriate to accomplish the specific aims of the project?
Are potential problems, alternative strategies, and benchmarks for success
presented? If the project is in the early stages of development, will the
strategy establish feasibility and will particularly risky aspects be
If the project involves clinical research, are the plans for 1) protection of human subjects from research risks, and 2) inclusion of minorities and members of both sexes/genders, as well as the inclusion of children, justified in terms of the scientific goals and research strategy proposed? Is the collaboration plan well-defined with clearly identified responsibilities for the U.S. and Indian collaborators? Is the management plan well-thought-out to build on and enhance existing research capacity/resource and to take advantage of the strengths of the U.S. and Indian collaborators?
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?
As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact/priority score, but will not give separate scores for these items.
Protections for Human Subjects
For research that involves human subjects but does
not involve one of the six categories of research that are exempt under 45 CFR
Part 46, the committee will evaluate the justification for involvement of human
subjects and the proposed protections from research risk relating to their
participation according to the following five review criteria: 1) risk to
subjects, 2) adequacy of protection against risks, 3) potential benefits to the
subjects and others, 4) importance of the knowledge to be gained, and 5) data
and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Human Subjects Protection and Inclusion Guidelines.
Inclusion of Women, Minorities, and Children
When the proposed project involves clinical research, the committee will evaluate the proposed plans for inclusion of minorities and members of both genders, as well as the inclusion of children. For additional information on review of the Inclusion section, please refer to the Human Subjects Protection and Inclusion Guidelines.
The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.
Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact/priority score.
Applications from Foreign Organizations
Select Agent Research
Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Resource Sharing Plans
Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: 1) Data Sharing Plan; 2) Sharing Model Organisms; and 3) Genome Wide Association Studies (GWAS).
Budget and Period of Support
Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by the Center for Scientific Review(assignments will be shown in the eRA Commons), in accordance with NIH peer review policy and procedures, using the stated review criteria.
As part of the scientific peer review, all applications:
Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications . Following initial peer review, recommended applications will receive a second level of review by the appropriate national Advisory Council or Board. The following will be considered in making funding decisions:
After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons.
Information regarding the disposition of applications is available in the NIH Grants Policy Statement.
If the application is under consideration for funding, NIH
will request "just-in-time" information from the applicant as
described in the NIH Grants
A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee business official.
Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.
Any application awarded in response to this FOA will be subject to the DUNS, CCR Registration, and Transparency Act requirements as noted on the Award Conditions and Information for NIH Grants website.
All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.
Cooperative Agreement Terms and Conditions of Award
When multiple years are involved, awardees will be required to submit the Non-Competing Continuation Grant Progress Report (PHS 2590) annually and financial statements as required in the NIH Grants Policy Statement.
The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.
We encourage inquiries concerning this funding opportunity
and welcome the opportunity to answer questions from potential applicants.
GrantsInfo (Questions regarding application instructions and
process, finding NIH grant resources)
eRA Commons Help Desk(Questions regarding eRA Commons
registration, tracking application status, post submission issues)
Phone: 301-402-7469 or 866-504-9552 (Toll Free)
Yuan Liu, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
David Shurtleff, Ph.D.
National Institute on Drug Abuse (NIDA)
Pamela Y. Collins, M.D., MPH
National Institute of Mental Health (NIMH)
Seetha Bhagavan, Ph.D.
Center for Scientific Review (NIH)
Tijuanna DeCoster, MPA
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute on Drug Abuse (NIDA)
Joy R. Knipple
National Institute of Mental Health (NIMH)
Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Parts 74 and 92.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Office of Extramural
National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
Department of Health
and Human Services (HHS)